What MPI is and why it matters in 2026
Magnetic Particle Imaging is a radiation-free, tomographic imaging modality that directly detects and quantifies superparamagnetic iron oxide nanoparticles (SPIONs) by exploiting their nonlinear magnetization response to applied magnetic fields, producing zero-background tissue signal with high temporal and spatial resolution. Unlike MRI, which detects proton resonance, MPI exploits the saturable, nonlinear magnetization of SPIONs governed by Langevin theory — an inherent zero-background imaging contrast that MRI and CT cannot replicate.
A spatially structured magnetic field incorporating a field-free region (FFR) — either a field-free point (FFP) or field-free line (FFL) — is scanned across the imaging volume. Only particles within the FFR contribute a time-varying signal detectable by receive coils; particles outside are magnetically saturated and silent. First proposed by Gleich and Weizenecker in 2005, MPI has matured from a theoretical construct into an established preclinical platform now approaching clinical translation across cardiovascular, oncological, neurological, and interventional domains.
The FFR is the spatial zone within an MPI scanner where the magnetic field is near zero, allowing SPIONs located there to respond to the applied excitation field and generate a detectable signal. All particles outside the FFR are saturated and contribute no signal, creating the modality’s characteristic zero-background contrast. The FFR can be configured as a field-free point (FFP) or a field-free line (FFL), each with distinct SNR and scanning trade-offs.
This landscape analyses the innovation landscape across hardware systems, tracer design, image reconstruction, and application verticals, drawing on patent filings and literature records spanning 2013–2025. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full industry.
Magnetic Particle Imaging (MPI) produces zero-background tissue signal by exploiting the nonlinear magnetization response of superparamagnetic iron oxide nanoparticles (SPIONs) to a spatially structured magnetic field, a physical principle fundamentally distinct from MRI’s proton resonance detection.
Three phases of MPI innovation: from theory to clinical threshold
MPI innovation from 2013 to 2025 progressed through three discernible phases — foundational, diversification, and clinical-translation engineering — each defined by distinct milestones in hardware capability, tracer performance, and application breadth.
The foundational phase (2013–2015) established theoretical and experimental baselines. Key milestones include first demonstrations of SPION design principles for MPI at the University of Hong Kong (2013), the first MPI cell tracking study demonstrating 200-cell detection in rat brain at UC Berkeley (2015), and multi-color MPI feasibility demonstration by Philips GmbH (2015). The University of Lübeck’s 2015 review summarized the field’s state at that inflection point.
The development and diversification phase (2016–2020) saw consolidation of preclinical platforms and expansion into new application domains. Human-scale brain imaging hardware was demonstrated by the Hamburg-Eppendorf group in 2019, detecting iron concentrations as low as 263 pmol Fe/mL. Cardiovascular MPI was validated for aneurysm hemodynamics at 46 volumes per second in 2016. The OpenMPIData initiative from Hamburg-Eppendorf in 2020 signaled growing community infrastructure by democratizing access to experimental datasets. Point-of-care MPI systems emerged from ETRI, South Korea, in 2020.
The clinical-translation and engineering maturity phase (2021–2025) reflects deliberate clinical-pathway engineering. Active patents from the University of California (EP, 2023) and Mitsubishi Electric (JP, 2025) address hardware optimization and FFL-based reconstruction respectively. Aselsan’s calibration methodology patents (EP 2024, JP 2023) address a critical bottleneck — system matrix acquisition time — that has constrained routine clinical deployment. Intraoperative applications from Leiden University Medical Center (2021) and breast-conserving surgery margin assessment from Harvard Medical School (2021) represent the frontier of translational activity in this dataset.
“Human-scale brain imaging hardware demonstrated iron detection at 263 pmol Fe/mL, operable in unshielded environments such as intensive care units — a threshold that reframes MPI from laboratory instrument to bedside tool.”
Hardware architectures and SPION tracer design: the twin rate-limiters
MPI’s clinical viability depends on two interlocking engineering challenges: generating and scanning a field-free region at clinically safe dB/dt and SAR levels in human-scale bore geometries, and synthesising SPION tracers whose physical properties are optimised for MPI rather than MRI.
FFR Hardware Architectures
The dominant patent-level innovation in this dataset focuses on excitation waveform engineering and FFR translation efficiency. The University of California’s pulsed MPI system (EP, 2023) introduces a pulse sequence generator driving FFR location shifts via excitation magnetic fields, enabling optimised scan time, amplifier heating, and dB/dt management. Their complementary patent on improved MPI techniques (EP, 2023) incorporates high-Q receive coils and multi-resolution scanning via intermodulated low and radio-frequency excitation signals. Mitsubishi Electric’s 2025 FFL-based device (JP, 2025) generates corrected projection data using sensitivity correction applied to system-function-derived projection data, with the FFL region scanned and rotated for full volumetric coverage. According to WIPO filing records, FFL geometries offer SNR advantages over FFP configurations at equivalent gradient strengths, and Mitsubishi’s filing signals industrial-level commitment to FFL as the preferred clinical architecture.
A self-shielded human-brain-scale MPI scanner developed by the University Medical Center Hamburg-Eppendorf achieved iron detection at 263 pmol Fe/mL and was designed to operate in unshielded environments such as intensive care units, as reported in 2019.
SPION Tracer Design
SPION performance is the single largest determinant of MPI sensitivity, resolution, and quantitativeness. Langevin theory predicts that the optimal SPION core diameter for MPI signal generation is approximately 25–30 nm — larger than typical commercial iron oxides — with narrow size distribution, low anisotropy, and controlled surface chemistry. University of Hong Kong researchers established how core size, size distribution, and surface modification govern spatial resolution and sensitivity (2013). Multicore nanoparticle formulations (MCP 3) demonstrated superior in vivo MPI performance over commercial Resovist in rat angiography at dose reductions, as reported by Charité Berlin in 2020. Philips GmbH’s multi-color MPI work established that particles in different environments or of different types produce separable spectral signatures, enabling simultaneous multi-tracer imaging (2015).
Bimodal marker fabrication combining MPI and MRI visibility was demonstrated using KLB and Bayoxide E8706 nanoparticle coatings on non-metallic guidewires (University Hospital Schleswig-Holstein, 2022). The absence of filed SPION composition patents in this dataset suggests either concentration in literature through academic disclosure, or a gap in prosecution strategy — an opportunity for pharmaceutical and nanomaterial companies to build IP position around optimised MPI-specific tracers.
Analyse the full MPI patent landscape and SPION tracer IP landscape with PatSnap Eureka.
Explore MPI Patents in PatSnap Eureka →Image reconstruction and system calibration: the clinical deployment bottleneck
MPI reconstruction is fundamentally an ill-posed inverse problem, and the time required to acquire system matrices represents the primary commercial bottleneck preventing routine clinical deployment of MPI scanners today.
Two paradigms coexist: system matrix (SM)-based reconstruction, which requires time-consuming empirical calibration scans, and model-based reconstruction, which derives reconstruction operators from mathematical forward models. The SM approach is reviewed extensively by the Beijing Institute of Technology (2021), identifying background signal contamination and field-of-view limitations as primary challenges. Mathematical model-based approaches are characterised by the University of Bremen (2018), framing the forward operator as a Fredholm integral of the first kind. Quality enhancement through merging multi-angle scan data is addressed by Hochschule Darmstadt (2022).
The most operationally significant calibration advance in this dataset is Aselsan’s coded calibration scene, which distributes multiple nanoparticle samples in a volume larger than the field of view, moved linearly and rotationally to populate the system matrix efficiently. Active patents were granted in Europe (EP 2024) and Japan (JP 2023). This approach represents a freedom-to-operate risk for any commercial MPI scanner developer deploying similar calibration architectures.
Aselsan (Turkey) holds two active patents on MPI system matrix calibration methodology — EP 2024 and JP 2023 — covering a coded calibration scene approach that distributes nanoparticle samples across a volume larger than the field of view to populate the system matrix more efficiently, addressing the primary commercial bottleneck for clinical MPI deployment.
Temperature monitoring during liver tumour ablation using MPI has been validated with 1°C mean absolute deviation accuracy (University Medical Center Hamburg-Eppendorf, 2020). This level of thermometric precision — enabled by the temperature-dependent shift in SPION magnetisation curves — is a direct product of accurate system calibration and is clinically relevant for ablation margin control, a domain where standards bodies such as ISO are actively developing thermal therapy guidance frameworks.
Application domains: where MPI is winning and where it is emerging
MPI’s zero-background contrast and high temporal resolution have translated into demonstrable advantages across six application domains, each at a different stage of preclinical validation and clinical readiness.
Cardiovascular and Vascular Imaging
MPI’s combination of high temporal resolution — 46 volumes per second — and zero-background signal makes it particularly suited for dynamic blood pool imaging. Aneurysm hemodynamics assessment was demonstrated against DSA and 4D phase-contrast MRI benchmarks in 2016. Moving table MPI extending the field of view for whole-vasculature imaging was demonstrated at Hamburg-Eppendorf in 2018. In vivo rat aorta and inferior vena cava angiography confirmed dose-dependent sensitivity with novel multicore particles (Charité Berlin, 2020). Standards bodies including IEEE have begun addressing medical imaging system performance benchmarks that will be relevant as MPI cardiovascular systems approach regulatory submission.
Neuroimaging and Stroke
The human-brain-scale MPI scanner operating at intensive-care-unit conditions (2019) represents the most advanced hardware demonstration for neurological applications in this dataset. A dedicated neuroimaging review articulates use cases spanning stroke perfusion monitoring, traumatic brain injury, and real-time cerebral blood flow quantification (2019). MPI’s absence of ionising radiation and susceptibility artefacts positions it as a candidate for bedside stroke monitoring — a gap not currently addressable by CT (radiation) or MRI (susceptibility artefacts, incompatibility with metallic implants).
Oncology and Theranostics
Tumour-specific SPION accumulation was imaged in CT26 and MC38 murine colon carcinoma models via both intratumoral and intravenous delivery using a point-of-care MPI platform (Eulji University, 2022). Tumour self-homing of circulating tumour cells was visualised in a murine breast cancer model (University of Western Ontario, 2020). Intraoperative margin assessment in breast-conserving surgery was proposed with both a handheld detector and small-bore scanner configuration (Harvard Medical School, 2021). MPI-guided hyperthermia with temperature monitoring validated for liver tumour ablation used Lissajous scanning MPI as a multifunctional platform providing nanoparticle localisation, remote thermometry, and focused hyperthermia delivery (Charité Berlin, 2020), with 1°C mean absolute deviation thermometric accuracy (Hamburg-Eppendorf, 2020).
Cell Tracking and Regenerative Medicine
MPI’s direct SPION detection enables quantitative longitudinal cell tracking not achievable with SPION-based MRI, which detects particles only indirectly via proton relaxation effects. Neural graft clearance was monitored over 87 days in rat brain with 200-cell in vitro detection sensitivity (UC Berkeley, 2015). Iron-labelled tumour cell metastasis and cell death were tracked in vivo using combined bioluminescence and MPI (Michigan State University, 2022). Research published in journals indexed by Nature has highlighted quantitative cell tracking as one of MPI’s most differentiated capabilities relative to existing modalities.
Interventional Radiology and Intraoperative Navigation
Real-time 4D catheter tracking at 46 volumes per second for endovascular procedures was demonstrated in vitro in 2016. Freehand 3D MPI for sentinel lymph node biopsy in penile cancer, using SPION tracers combined with fluorescence guidance, was demonstrated clinically (Leiden University Medical Center, 2021). Nanoparticle swarm navigation — steering magnetite clouds at 8 mm/s with real-time MPI imaging feedback — opens robotic drug delivery pathways (Fraunhofer IMTE, 2021).
Fraunhofer IMTE demonstrated nanoparticle swarm navigation at 8 mm/s with real-time MPI imaging feedback in 2021, opening a robotically guided drug delivery paradigm in which MPI serves simultaneously as navigation sensor and delivery confirmation modality.
Map the full MPI application patent landscape across cardiovascular, oncology, and interventional domains with PatSnap Eureka.
Search MPI Application Patents in PatSnap Eureka →Geographic concentration and strategic implications for IP teams
MPI innovation within this dataset is concentrated in fewer than 10 primary institutional nodes, with Germany, the United States, and Asia representing the three dominant geographies — each with distinct IP profiles and strategic postures.
Germany is the dominant geography for MPI systems research in this dataset, led by the University Medical Center Hamburg-Eppendorf (UKE), which contributes across angiography, catheter tracking, moving table imaging, IVOCT integration, OpenMPI data infrastructure, and human-scale scanner development. The Charité – Universitätsmedizin Berlin contributes hyperthermia theranostics and temperature-resolved MPI. Fraunhofer IMTE (Lübeck) contributes nanoswarm actuation. The University of Lübeck and University Hospital Schleswig-Holstein contribute tracer development and bimodal marker work.
United States: The Regents of the University of California hold two active European patent grants covering pulsed MPI architectures and improved scanning techniques (both EP, 2023) — the only large-entity US-origin MPI patents with URLs in this dataset. UC Berkeley’s 2015 cell tracking work and Harvard Medical School’s 2021 intraoperative margin assessment work represent key translational contributions.
Asia: Mitsubishi Electric (Japan) filed the most recent MPI hardware patent in this dataset (JP, 2025), covering FFL-based imaging with sensitivity-corrected reconstruction. South Korean contributions include ETRI’s point-of-care 3D MPI system (2020) — a 20×33×45 cm³ device weighing under 100 kg — and Eulji University’s preclinical tumour imaging studies (2022). Chinese institutions — Beijing Institute of Technology, Beijing You’an Hospital/Capital Medical University, and Zhuhai People’s Hospital — contribute primarily to review literature covering reconstruction, applications, and liver imaging. Turkey: Aselsan holds two active patents on system matrix calibration methodology (EP 2024, JP 2023), representing an unexpected geography for MPI system-level IP.
“Aselsan’s coded calibration scene patents (EP 2024, JP 2023) represent freedom-to-operate risk for any commercial MPI scanner developer — IP strategists should conduct FTO analysis before deploying similar calibration architectures.”
Six forward-looking signals are discernible from 2021–2025 records: pulsed and multi-resolution excitation architectures (University of California, EP 2023); FFL-based human-scale scanners with sensitivity correction (Mitsubishi Electric, JP 2025); efficient system matrix calibration (Aselsan, EP 2024, JP 2023); intraoperative and point-of-care miniaturisation toward bedside and operating-room-compatible devices; nanoparticle swarm navigation and robotic theranostics at 8 mm/s (Fraunhofer IMTE, 2021); and immunotherapy and CAR T-cell tracking for months-long quantitative MPI monitoring of cancer immune responses (A*STAR Singapore, 2021). The NIH has identified quantitative cell tracking and theranostic imaging as priority areas in its biomedical imaging roadmap, directly aligning with MPI’s core technical differentiators. IP teams at medical device companies and pharmaceutical developers should monitor CN, JP, and KR filings closely as Asian industrial and academic actors are expected to be significant IP generators in the next filing cycle, per PatSnap’s innovation intelligence platform analysis.